Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Carcinoma, Non-Small-Cell Lung 8Squamous Cell Carcinoma of Head and Neck 2Pancreatic Neoplasms 2Triple Negative Breast Neoplasms 1Small Cell Lung Carcinoma 1Rhabdoid Tumor 1Neoplasms, Squamous Cell 1Neoplasms 1Neoplasm Metastasis 1Lung Neoplasms 1Leiomyosarcoma 1Histiocytoma, Malignant Fibrous 1Head and Neck Neoplasms 1Colorectal Neoplasms 1Choroid Plexus Neoplasms 1Central Nervous System Neoplasms 1Adult Solid Neoplasm 1

Interventions

Cisplatin 3pembrolizumab 2Taxes 2Paclitaxel 2fludarabine phosphate 1fludarabine 1Radiotherapy, Intensity-Modulated 1Radiotherapy 1Radiation 1Pemetrexed 1Nimorazole 1Erlotinib Hydrochloride 1Docetaxel 1Cyclophosphamide 1Carboplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Neoplasms, Squamous Cell × Erlotinib Hydrochloride × Clear all
NCT00076310 2026-04-15

OSI-774/Cisplatin/Taxotere in Head & Neck Squamous Cell Cancer

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
50 enrolled 11 charts
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Neoplasms, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡